Dare Bioscience Files 8-K Report
Ticker: DARE · Form: 8-K · Filed: Dec 16, 2024 · CIK: 1401914
Sentiment: neutral
Topics: sec-filing, 8-k, financials
TL;DR
Dare Bioscience filed an 8-K, mostly financial updates and other events.
AI Summary
On December 16, 2024, Dare Bioscience, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific new financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates Dare Bioscience is providing updated financial information and potentially disclosing other material events to the SEC.
Risk Assessment
Risk Level: low — The provided excerpt is a standard SEC filing notification and does not contain specific material events or financial performance data that would indicate high risk.
Key Players & Entities
- Dare Bioscience, Inc. (company) — Registrant
- Cerulean Pharma Inc. (company) — Former Company Name
- Tempo Pharmaceuticals Inc (company) — Former Company Name
- December 16, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing by Dare Bioscience, Inc.?
The filing is for a Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, covering Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported is dated December 16, 2024.
What is Dare Bioscience, Inc.'s state of incorporation and fiscal year end?
Dare Bioscience, Inc. is incorporated in Delaware and its fiscal year ends on December 31.
What were Dare Bioscience, Inc.'s former company names?
Dare Bioscience, Inc. was formerly known as Cerulean Pharma Inc. (name change effective 20090714) and Tempo Pharmaceuticals Inc (name change effective 20070604).
What is the principal executive office address for Dare Bioscience, Inc.?
The principal executive offices are located at 3655 Nobel Drive, Suite 260, San Diego, CA 92122.
Filing Stats: 1,752 words · 7 min read · ~6 pages · Grade level 19.2 · Accepted 2024-12-16 08:05:12
Filing Documents
- form8-k.htm (8-K) — 47KB
- ex99-1.htm (EX-99.1) — 34KB
- 0001493152-24-050117.txt ( ) — 267KB
- dare-20241216.xsd (EX-101.SCH) — 3KB
- dare-20241216_lab.xml (EX-101.LAB) — 33KB
- dare-20241216_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will,"
Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "objective," or the negative version of these words and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks and uncertainties. Actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking to advance the development of its product candidates, including Sildenafil Cream for the treatment of FSAD, on communicated timelines, or at all; failure or delay in starting, conducting and completing clinical trials of a product candidate, including the first Phase 3 clinical study of Sildenafil Cream, including due to lack of sufficient capital resources; Dar's ability to raise additional capital when and as needed to advance its product candidates, execute its business strategy and continue as a going concern; the inherent uncertainty of outcomes of clinical trials of drug products and Sildenafil Cream in particular given the complexity of FSAD and the limited clinical trial precedent from which to draw experience; the risk that, as with the Phase 2b RESPOND study, the planned Phase 3 study may fail to demonstrate statistically significant differences between Sildenafil Cream and placebo users in the co-primary and secondary efficacy endpoints even though the Phase 3 study will exclude patients with FSAD with concomitant orgasmic dysfunction and concomitant genital pain; the risk that development of Sildenafil Cream requires more clinical or nonclinical studies than Dar anticipates, including to generate additional data that may be nee
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DAR BIOSCIENCE, INC. Dated: December 16, 2024 By: /s/ Sabrina Martucci Johnson Name: Sabrina Martucci Johnson Title: President and Chief Executive Officer -4-